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Editorial 
Billions of people worldwide are affected with various forms of can-
cer of virtually any part of the human body. Despite vast amounts of 
funds being poured into cancer research, the production of a single 
drug, or a group of drugs, which may ‘cure’ cancer remains an elusive 
dream. The future is not so bleak, though. Many drugs have been 
approved recently which combat the cancerous growth and alleviate 
quality of life of the patient. Countless others are under trials. What 
follows is an attempt to summarize a few. 
Akt, or protein kinase B (PKB), is a serine/threonine protein kinase 
which acts as a mediator in many cellular processes. Three members 
in the Akt family have been identified until now, of which Akt1 is the 
molecule playing a key role in cell survival and metabolism. It acts 
mainly via the activation of receptor tyrosine kinases (RTK), and pro-
duces such effects as inhibition of apoptosis, promotion of cell cycle 
progression and stimulation of angiogenesis. Miltefosine is the only 
Akt inhibitor which has been approved (that too for leishmaniasis), 
while several others show promise in their pre-clinical trials. These 
have been divided into different classes according to their mode of 
actions, and some, like Perifosine have failed too. [1]. 
Poly(ADP-ribose) Polymerases (PARPs) are a group of 17 proteins 
which play a role in apoptosis, genetic maintenance, inflammatory 
responses and regulation of gene transcription. PARP inhibitors were 
developed as agents that seem to target cancer cells when they are 
undergoing DNA repair [2]. Olaparib (AZD2281) showed anti-tumor 
effects in patients with BRCA1/2 mutated cancers. Patients showed 
40% response rate in platinum sensitive ovarian cancer with 
germline BRCA1/2 mutations [3]. Rucaparib, another PARP inhibitor 
showed promising results with chemopotention when used with te-
mozolomide for metastatic melanoma [4]. 
c-Met is a proto-oncogene that encodes hepatocyte growth factor 
receptor (HGFR) [5]. It plays an important role in embryonic devel-
opment, organ morphogenesis and healing reactions [6]. Met is a 
membrane receptor stimulating cell motility, invasion, protection 
from apoptosis and angiogenesis. Dysregulated activity of c-Met can 
cause a wide variety of cancers, including colorectal, gastric carci-
noma, liver, thyroid, breast, pancreas, renal cell, ovary, prostate and 
melanoma [7]. c-Met inhibitors are quite recent drugs. Foretinib 
XL880 completed phase 2 clinical trial with indications for head and 
neck, gastric and renal cell carcinoma and is still experimental [8]. 
Cabozantinib (XL184) was approved by the U.S. Food and Drug Au-
thority in November 2012 for the treatment of medullary thyroid 
cancer. There are several drugs of this category undergoing trials and 
there is promise shown that these used in conjunction with other 
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chemotherapeutic agents will significantly alter the course of the dis-
ease [7]. 
Imatinib, a tyrosine Kinase Inhibitor, is being used widely for the 
treatment of chronic myeloid leukemia (CML) [9]. Nilotinib, Da-
satinib, Bosutinib and Ponatinib are newer drugs of this class ap-
proved for the treatment of imatinib resistant or intolerant CML [10, 
11]. 
Histone de-acetylase inhibitors (HDIs) are yet another class of futur-
istic anti-cancer drugs bring used. [12]. Vorinostat (SAHA) and ro-
midepsin (ISTODAX) are FDA approved for the treatment of cutane-
ous T cell lymphoma. Use of HDIs as other types of cancer shows 
moderate effects [13, 14].  
Vismodegib, a hedgehog pathway inhibitor has been recently ap-
proved for treatment of advanced basal cell carcinoma [15]. Cyclo-
pamine is the prototype inhibitor of the Sonic Hedgehog (Shh) path-
way and is currently undergoing preclinical and clinical studies as an 
agent in treatment of basal cell carcinoma, medulloblastoma and 
rhabdomyosarcoma [16, 17]. Saridegib, a synthetic analog of cyclo-
pamine, has shown encouraging results in phase I trial of advanced 
solid tumors [18, 19]. 
Heat Shock Protein (HSP) inhibitors, drugs which inhibit molecular 
chaperones, though still in phase II clinical trials, show promise in the 
treatment of a variety of malignancies [20]. 
Many rounds of preclinical and clinical trials are still needed to de-
termine accurately the potential of anticancer medicines. While 
many may show promise, there is still the question of their therapeu-
tic indices and toxicity profiles. Some of these agents may stop or 
revert the growth of a tumor but may adversely affect the patient’s 
health otherwise. Chemotherapy is an exciting and ever-growing 
field of research and intense work is being done which promises 
hope for health professionals and for the affected. 
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